Ifp Advisors, Inc Blueprint Medicines Corp Transaction History

Ifp Advisors, Inc

$2.42 Billion
Q2 2024

A detailed history of Ifp Advisors, Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Ifp Advisors, Inc holds 1,105 shares of BPMC stock, worth $96,610. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,105

Previous 1,105 -0.0%

Holding current value

$96,610

Previous $104,000 14.42%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Jul 30, 2024	BUY	$73.17 - $99.79 $80,852 - $110,267	1,105 New	1,105 $104,000
Q4 2022 Feb 07, 2023	SELL	$41.06 - $66.48 $410 - $664	-10 Reduced 10.0%	90 $8,000
Q2 2022 Sep 06, 2022	BUY	$45.23 - $70.15 $4,523 - $7,015	100 New	100 $9,000
Q2 2022 Aug 12, 2022	SELL	$45.23 - $70.15 $4,523 - $7,015	-100 Closed	0 $0
Q1 2022 Sep 06, 2022	BUY	$54.1 - $110.08 $54 - $110	1 Added 1.01%	100 $6,000
Q4 2021 Jan 12, 2022	BUY	$94.25 - $115.99 $848 - $1,043	9 Added 10.0%	99 $11,000
Q3 2021 Oct 06, 2021	SELL	$80.98 - $109.47 $809 - $1,094	-10 Reduced 10.0%	90 $9,000
Q2 2021 Jul 13, 2021	SELL	$82.78 - $101.0 $2,069 - $2,525	-25 Reduced 20.0%	100 $9,000
Q1 2021 Apr 30, 2021	BUY	$90.71 - $108.28 $6,712 - $8,012	74 Added 145.1%	125 $12,000
Q4 2020 Jan 25, 2021	SELL	$92.08 - $124.48 $1,012 - $1,369	-11 Reduced 17.74%	51 $6,000
Q2 2020 Aug 05, 2020	BUY	$57.09 - $79.27 $1,484 - $2,061	26 Added 72.22%	62 $5,000
Q1 2020 May 12, 2020	SELL	$48.11 - $82.22 $59,752 - $102,117	-1,242 Reduced 97.18%	36 $3,000
Q3 2019 Nov 07, 2019	BUY	$72.9 - $101.41 $93,166 - $129,601	1,278 New	1,278 $94,000
Q1 2019 May 15, 2019	SELL	$48.7 - $86.6 $1,120 - $1,991	-23 Closed	0 $0
Q3 2018 Oct 25, 2018	BUY	$58.91 - $78.32 $1,354 - $1,801	23 New	23 $0

Others Institutions Holding BPMC

# of Institutions

351

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.22B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.

Account